$PYPD News
Last published 1d ago
- 1d agoPYPDPolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswireD-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing
- 1d agoPYPDPolyPid Third Quarter 2026 Conference Call - POLYPID LTDEarnings Call TranscriptsThank you all for joining PolyPID's third quarter 2026 earnings conference call. Earlier today, PolyPid released its financial results for the three and nine months ended September 30th, 2026. A copy of the press release
- 2w agoPYPDPolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026GlobeNewswirePETACH TIKVA, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by
- 2w agoPYPDPolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot InfectionsGlobeNewswireCompany to host virtual Investor Day today at 11:30 AM ET, featuring key opinion leader Warren S. Joseph, DPM, FIDSA All scheduled FDA interactions on track and aligned with D-PLEX₁₀₀ November 28, 2026 PDUFA goal
- 3w agoPYPDPolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026GlobeNewswirePETACH TIKVA, Israel, Oct. 21, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by
- 4w agoPYPDPolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026GlobeNewswireManagement to outline ‘PolyPid 2030’, the Company’s long-term vision and pipeline strategy Event to feature Warren S. Joseph, DPM, FIDSA, a nationally recognized specialist in lower extremity infectious diseases
- 1mo agoPYPDPolyPid Announces Participation in Upcoming Fall Investor ConferencesGlobeNewswirePETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by
- 3mo agoPYPDPolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsGlobeNewswireFDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization Partnership with
- 3mo agoPYPDPolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026GlobeNewswirePETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by
- 3mo agoPYPDPolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀GlobeNewswirePDUFA target action date of November 28, 2026, approximately one quarter ahead of Company’s previously communicated guidance FDA identified no Filing review issues Acceptance triggers $15 million milestone payment,
- 3mo agoPYPDPolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and CanadaGlobeNewswirePolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties
- 5mo agoPYPDPolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀GlobeNewswireIf approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter of 2027 PETACH TIKVA, Israel, June 01,
- 5mo agoPYPDPolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor ConferenceGlobeNewswirePETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment
- 6mo agoPYPDPolyPid Provides Corporate Update and Reports First Quarter 2026 Financial ResultsGlobeNewswireInitiated NDA Submission to the FDA for D-PLEX₁₀₀ ; Completion Expected Imminently U.S. Commercial Partnership Discussions in Late Stages Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May
- 6mo agoPYPDPolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026GlobeNewswirePETACH TIKVA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by
- 6mo agoPYPDPolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual MeetingGlobeNewswireAnalysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PETACH TIKVA, Israel,
- 7mo agoPYPDPolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026GlobeNewswirePETACH TIKVA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment
- 7mo agoPYPDPolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDAGlobeNewswirePolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 2026 (GLOBE
- 8mo agoPYPDPolyPid Announces Participation in Upcoming Investor ConferencesGlobeNewswirePETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment
- 9mo agoPYPDPolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewswireThe Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX₁₀₀ Positive FDA Pre-NDA Feedback Supports Rolling NDA Review; Submission Expected to Begin by the End of the First Quarter of 2026
- 9mo agoPYPDPolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026GlobeNewswirePETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that
- 11mo agoPYPDPolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of DirectorsGlobeNewswirePETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of
- 11mo agoPYPDRoth Capital KOL Webinar with Dr. Steven Wexner (MedStar Health) - Polypid Ltd.Earnings Call TranscriptsAll right. Good morning, everyone. My name is Bubalan. I'm a Managing Director and Senior Biotech Analyst at Roth Capital Partners. I specialize in emerging companies in the SMIT cap space, particularly in the pharma and
- 11mo agoPYPDPolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA SubmissionGlobeNewswirePETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received
- 11mo agoPYPDPolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025GlobeNewswirePETACH TIKVA, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will
- 1y agoPYPDPolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswireFace-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial
- 1y agoPYPDPolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"GlobeNewswirePETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company focused on improving surgical outcomes, today announced
- 1y agoPYPDPolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025GlobeNewswirePETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that
- 1y agoPYPDPolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical CongressGlobeNewswirePETACH TIKVA, Israel, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that
- 1y agoPYPDPolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities ConferenceGlobeNewswirePETACH TIKVA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that
- 1y agoPYPDPolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀GlobeNewswirePETACH TIKVA, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the
- 1y agoPYPDPolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment ConferenceGlobeNewswirePETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that
- 1y agoPYPDPolyPid to Present at the 14th Meeting of the Israel Controlled Release Society ConferenceGlobeNewswirePETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that
- 1y agoPYPDPolyPid Ltd. (PYPD) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoPYPDPolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsGlobeNewswirePositive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting GLP-1 Receptor
- 1y agoPYPDPolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical OfficerGlobeNewswirePETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the
- 1y agoPYPDPolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025GlobeNewswirePETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that
- 1y agoPYPDPolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss MarketGlobeNewswirePolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of weekly injections.
- 1y agoPYPDPolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial ResultsGlobeNewswireThe Company Anticipates that with this Additional Funding, PolyPid's Runway would be Extended beyond Anticipated U.S. Food and Drug Administration ("FDA") Approval of D-PLEX₁₀₀.The Company Recently Announced Successful
- 1y agoPYPDBriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call TranscriptGlobeNewswireIn a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal colorectal surgery
- 1y agoPYPDPolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary EndpointsGlobeNewswireD-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions.The trial successfully met all key secondary efficacy
- 1y agoPYPDPolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025GlobeNewswirePETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a
- 1y agoPYPDPolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025GlobeNewswirePETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast
- 1y agoPYPDPolyPid Provides Corporate Update and Reports First Quarter 2025 Financial ResultsGlobeNewswirePolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100, with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations,
- 1y agoPYPDPolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025GlobeNewswirePETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report
- 1y agoPYPDPolyPid to Participate in The Citizens Life Sciences ConferenceGlobeNewswirePETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's
- 1y agoPYPDPolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site InfectionsGlobeNewswirePETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful
- 1y agoPYPDPolyPid to Participate in the 37th Annual ROTH ConferenceGlobeNewswirePETACH TIKVA, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's
- 1y agoPYPDPolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial ResultsGlobeNewswirePositive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enrolled more than 700 Patients to Date; Enrollment Completion Expected in March 2025, with
- 1y agoPYPDPolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewswirePETACH TIKVA, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's